Literature DB >> 7372791

Domperidone, an extracerebral inhibitor of dopamine receptors, stimulates thyrotropin and prolactin release in man.

G Delitala, L Devilla, G Lotti.   

Abstract

Domperidone, an extracerebral dopamine receptor antagonist, was given im to 12 normal subjects and to a group of patients with subclinical hypothyroidism to study its effect on PRL and TSH secretion. Domperidone induced in all subjects a quick and marked increment of serum PRL. At 180 min, the levels remained high. A small but significant increase of TSH was also observed in normal as well as in hypothyroid subjects. Since domperidone does not cross the blood-brain barrier, the hormonal changes observed may be mediated through the pituitary and median eminence, tissues which lie outside of the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7372791     DOI: 10.1210/jcem-50-6-1127

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink.

Authors:  Jake E Thistle; Jessica L Petrick; Baiyu Yang; Marie C Bradley; Barry I Graubard; Katherine A McGlynn
Journal:  Cancer Epidemiol       Date:  2018-07-06       Impact factor: 2.984

3.  Cholinergic independent dopaminergic regulation of motilin release in man.

Authors:  A Funakoshi; M Matsumoto; K Sekiya; I Nakano; H Shinozaki; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1983-12

4.  Increased serum prolactin but normal TSH during prolonged domperidone treatment in children.

Authors:  A R Deprettere; K J Van Acker; M V Du Caju
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

Review 5.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.